Información del artículo
El Comité Asesor de Vacunas de la Asociación Española de Pediatría comenta las novedades sobre vacunas ocurridas en el año 2003 y aconseja hacer algunas modificaciones del Calendario Vacunal. Se mantiene la recomendación de sustituir la vacuna de polio oral por polio inactivada, suprimiendo la quinta dosis; se insiste en la introducción de la vacuna conjugada de neumococo y la de la varicela. Con respecto a la vacuna contra meningococo C se comenta la mejora que supone poder inmunizar con sólo dos dosis. De acuerdo con la información recibida de la Agencia Europea del Medicamento, no existe ningún motivo fundado para prescindir del uso de preparados hexavalentes
Palabras clave:
Enfermedades inmunoprevenibles
Calendario vacunal
Estrategias vacunales
Inmunizaciones
Vacunas
Vacunas combinadas
The Vaccine Assessment Committee of the Spanish Association of Pediatrics discusses vaccine developments in 2003 and recommends some modifications to the vaccination schedule. The recommendation of substituting the oral polio vaccine for the inactivated polio vaccine, suppressing the fifth dose, is maintained. The introduction of the conjugate pneumococcal vaccine and the varicella vaccine is stressed. Concerning the meningococcal C vaccine, the improvement introduced by being able to immunize with just two doses is discussed. In agreement with the information received from the European Medicines Agency, there appear to be no well-founded reasons to abandon hexavalent preparations
Keywords:
Vaccine preventable diseases
Immunization schedule
Vaccination strategies
Immunizations
Vaccines
Combined vaccines
El Texto completo está disponible en PDF
Bibliografía
[1.]
Comité Asesor de Vacunas de la AEP.
Calendario vacunal de la AEP 1999.
An Esp Pediatr, 51 (1999), pp. 120-126
[2.]
Comité Asesor de Vacunas de la AEP.
Calendario vacunal de la Asociación Española de Pediatría 2001–2002.
An Esp Pediatr, 55 (2001), pp. 30-38
[3.]
Calendario Vacunal de la Asociación Española de Pediatría 2003.
An Pediatr (Barc), 58 (2003), pp. 257-262
[4.]
R. Dal-Ré, J. Arístegui, A. González.
Inmunidad frente a la difteria en adultos jóvenes en España.
Med Clin (Barc), 17 (1995), pp. 676
[5.]
P. Garcia-Corbeira, R. Dal-Ré, J. García de Lomas, L. Aguilar.
Low prevalence of diphtheria immunity in the Spanish population: Results of a cross-sectional study.
Vaccine, 17 (1999), pp. 1978-1982
[6.]
M. Español, C. Muñoz, G. Prats.
Inmunidad frente a la difteria de una muestra representativa de la población de Barcelona determinada mediante una técnica inmunoenzimática.
Vacunas Investigación y Práctica, 1 (2000), pp. 59-64
[7.]
Servicio de vigilancia epidemiológica.
Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España. Año 2000.
Bol Epidemiol Semanal, 9 (2001), pp. 101-112
[8.]
Servicio de vigilancia epidemiológica.
Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Ministerio de Sanidad y Consumo. Comentario epidemiológico de las Enfermedades de Declaración Obligatoria y Sistema de Información Microbiológica. España. Año 2001.
Bol Epidemiol Semanal, 10 (2002), pp. 49-60
[9.]
M. Campins-Martí, H.K. Cheng, K. Forsyth, N. Guiso, S. Halperin, L.M. Huang, et al.
Recommendations are needed for adolescents and adults pertussis immunisation rationale and consideration.
Vaccine, 20 (2002), pp. 641-646
[10.]
World Health Organization.
Certification of poliomyelitis eradicaction. European Region, June 2001.
Weekly Epidemiological Record, 27 (2002), pp. 221-223
[11.]
P. Beutels, W.J. Edmunds, F. Antoñanzas, G.A. De Wit, D. Evans, R. Feilden, et al.
Economic Evaluation of vaccination programmes. A consensus statement focusing on viral hepatitis.
Pharmacoeconomics, 20 (2002), pp. 1-7
[12.]
P.L. Lopalco, L. Salleras, S. Barbuti, C. Germinario, M. Bruguera, M. Buti, et al.
Hepatitis A and B in children and adolescentswhat can we learn from Puglia (Italy) and Catalonia (Spain)?.
Vaccine, 19 (2000), pp. 470-474
[13.]
K. Pushparajah, P. Ramnarayan, A. Maniyar, R. Paget, J. Britto.
Continued threat of Haemophilus influenzae type B disease in the U.K.
Lancet, 361 (2003), pp. 90
[14.]
J. Eskola, J. Ward, R. Dagan, D. Goldblatt, F. Zepp, C.A. Siegrist.
Haemophilus influenzae tipo b (Hib) conjugate vaccines administered in combination with DTP containing acellular pertussis and protection against invasive Hib disease.
Lancet, 354 (1999), pp. 2036-2068
[15.]
H.J. Schmitt, F. Zepp, S. Muschenbord, G. Sumenicht, A. Schuind, K. Beutel, et al.
Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphteria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Eur J Pediatr, 157 (1998), pp. 208-214
[16.]
F. Zepp, A. Schuind, C. Meyer, R. Sanger, A. Kaufhold, P. Willems.
Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants.
Pediatrics, 109 (2002), pp. e58
[17.]
American Academy of Pediatrics.
Committee on Infectious Diseases. Age for Routine Administration of the second dose of measles-mumps-rubella vaccine.
Pediatrics, 101 (1998), pp. 129-133
[18.]
W.A. Orenstein, P.M. Strebel, M. Papania, R.W. Sutter, W.J. Bellini, S.L. Cochi.
Measles eradication: Is it in out future?.
Am J Public Health, 90 (2000), pp. 1521-1525
[19.]
S. Mateo, R. Cano, C. García.
Changing epidemiology of meningococcal disease in Spain, 1989–1997.
Eurosurveillance, 2 (1997), pp. 71-74
[20.]
P. Richmond, R. Borrow, D. Goldblatt, J. Findlow, S. Martin, R. Morris, et al.
Ability of 3 Different Meningococcal C Conjugate Vaccines to Induce Immunologic Memory a Single dose In UK Toddlers.
J Infect Dis, 183 (2001), pp. 160-163
[21.]
R. Borrow, D. Goldblatt, A. Finn, J. Southern, L. Asthon, N. Andrews, et al.
Immunogenicity of and immunological memory to a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom.
Infect Immun, 71 (2003), pp. 5549-5555
[22.]
J. Casado Flores, A. Fenol, J. Arístegui, C. Rodrigo de Liria, J.M. Martinón.
Fernández C y Grupo para el Estudio de la Meningitis Neumocócica. Meningitis neumocócica en niños españoles: incidencia, serotipos y resistencia antibiótica. Estudio prospectivo multicéntrico.
An Esp Pediatr, 57 (2002), pp. 287-289
[23.]
E. Bernaola, J. Arístegui, M. Herranz, C. García-Calvo, C. Fernández.
Estudio de la incidencia de enfermedad neumocócica invasora entre 0–5 anos en el Pais Vasco y Navarra.
An Esp Pediatr, 57 (2002), pp. 301-309
[24.]
C. Pérez, G. Solis, D. Miguel, P. De la Iglesia, G. Viejo, M. Martin.
Factores predictivos de enfermedad neumococica invasora: estudio de casos controles.
An Esp Pediatr, 57 (2002), pp. 310-316
[25.]
V. Pineda, D. Fontanals, H. Larramona, M. Domingo, J. Antón, F. Segura.
Epidemiology of invasive Streptococcus pneumoniae infections in children in an area of Barcelona.
Spain Acta Pediatr, 91 (2002), pp. 1251-1256
[26.]
S. Black, H. Shinefield, B. Fireman, E. Lewis, P. Ray, J.R. Hansen, et al.
and The Northern California Kaiser Permanent Vaccine Study Center Group. Efficacy, safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in children.
Pediatr Infect Dis J, 19 (2000), pp. 187-195
[27.]
C.G. Whitney, M.M. Farley, J. Hadler, L.H. Harrison, N.M. Bennett, R. Lynfield, et al.
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
N Engl J Med, 348 (2003), pp. 1737-1746
[28.]
A. Fenoll, Y. Jado, D. Vicioso, S. Berron, J.E. Yuste, J. Casal.
Streptococcus pneumoniae in children in Spain: 1990–1999.
Acta Pediatr, 435 (2000), pp. 44-50
[29.]
Comité Asesor de Vacunas de la Asociación Española de Pediatria.
Incidencia de la infección neumocócica invasora en niños menores de dos años. Vacuna neumocócica conjugada heptavalente. Situacion en España.
An Esp Pediatr, 57 (2002), pp. 287-289
[30.]
M.D. Decker.
Principles of pediatric combination vaccines and practical issues related to use in clinical practice.
Pediatr Infect Dis J, 20 (2001), pp. 10-18
[31.]
EMEA reviews hexavalent vaccines: Hexavac an Infanrix Hexa London 28 April 2003/EMEA/8519/03
[32.]
EMEA update on hexavalent vaccines: Hexavac and Infanrix Hexa London 01 December 2003/EMEA/CPMP/5889/03
[33.]
G. Taliani, G.B. Gaeta.
Hepatitis A: Post-exposure prophylaxis.
Vaccine, 21 (2003), pp. 2234-2237
[34.]
H.J. Schmitt, G. Petersen, B. Corsaro.
Immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (Prevenar®) coadministred with a DTaP-IPV-HBV/Hib vaccine (Infanrix® Hexa) 43nd Interscience Conference on Antimicrobial Agents and Chemoteraphy (ICAAC).
Chicago, Abs.G-92 (2003),
[35.]
H.J. Schmitt, G. Petersen, B. Corsaro.
Immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (Prevenar®) coadministerd with a DTaP-IPV-HBV/Hib vaccine (Infanrix® Hexa) 42nd Interscience Conference on Antimicrobial Agents and Chemoteraphy (ICAAC).
San Diego, G-835 (2003), pp. 242
[36.]
C. Olivier, J.G. Liese, S. Stojanov, Tetelboum, et al.
Immunogenicity and safety of the 7-valent pneumococcal conjugate vaccine (7vPnC-prevenar®) coadministerd with a hexavalent DTaP-IPVHBV- Hib vaccine (Hexavac®) 42nd Interscience Conference on Antimicrobial Agents and Chemoteraphy (ICAAC).
San Diego, G-836 (2003), pp. 242
[37.]
J.C. Tejedor, F. Omeñaca, J. García-Sicilia, J. Verdaguer.
Coadministration of DTaP-IPV-HBV/Hib with meningococcal C conjugate vaccine 21st Annual Meeting of the ESPID, abs-293 (2003), pp. 147
[38.]
E.M. Poellabauer, C. Himly, A. Loew-Baselli, B.G. Pavlova.
Group C meningococcal TT conjugate vaccine (Neisvac-C®) absence of immunological interference with hepatitis BIPV and accelular pertussis aP 21st Annual Meeting of the ESPID, abs-278 (2003), pp. 139
Copyright © 2004. Asociación Española de Pediatría
